ALK-Abello B

CPSE:ALKB

Denmark / Healthcare / Pharmaceuticals

Overview

News

5Y Historical Financials

Stock Price

181.50 DKK


Key Metrics	Latest
Total Revenue	5.708 B
Adjusted EBITDA	1.438 B
EBITDA Margin	25.2%
Net Profit Margin	16.5%
Total Assets	8.188 B
Total Debt	800 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Mar-24	Mar-25

Revenue	3,491.00	3,916.00	4,511.00	4,824.00	5,537.00	5,708.00	1,351.00	1,522.00
% Growth		0.12	0.15	0.07	0.15			0.13

Adjusted EBITDA	311.00	469.00	637.00	834.00	1,280.00	1,438.00	382.00	540.00
% Margin	0.09	0.12	0.14	0.17	0.23	0.25	0.28	0.35

Adjusted EBIT	174.00	310.00	472.00	667.00	1,097.00	1,250.00	316.00	469.00
% Margin	0.05	0.08	0.10	0.14	0.20	0.22	0.23	0.31

Adjusted Net Income	43.50	232.32	336.48	486.74	819.44	941.44	232.00	354.00
% Margin	0.01	0.06	0.07	0.10	0.15	0.16	0.17	0.23

Adjusted Basic EPS	0.20	1.06	1.53	2.20	3.70	4.06	1.10	1.60

Supporting Calculations

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
DKK	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Mar-25	Mar-24	Mar-25
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	3,491	3,916	4,511	4,824	5,537	5,708	1,351	1,522
% Growth	NA	12.2%	15.2%	6.9%	14.8%			12.7%

Cost of Revenue	(1,458)	(1,514)	(1,719)	(1,788)	(1,979)	(2,023)	(462)	(506)
Gross Profit	2,033	2,402	2,792	3,036	3,558	3,685	889	1,016
% Revenue	58.2%	61.3%	61.9%	62.9%	64.3%	64.6%	65.8%	66.8%

Research and Development	(515)	(631)	(665)	(618)	(531)	(530)	(130)	(129)
Selling and Marketing	(1,125)	(1,223)	(1,380)	(1,422)	(1,564)	(1,549)	(354)	(339)
General and Admin	(238)	(240)	(276)	(331)	(369)	(358)	(90)	(79)
Other Inc / (Exp)	(25)	(7)	(4)	(8)	(33)	(34)	1	0
Total Operating Exp	(1,903)	(2,101)	(2,325)	(2,379)	(2,497)	(2,471)	(573)	(547)

Operating Income	130	301	467	657	1,061	1,214	316	469
% Revenue	3.7%	7.7%	10.4%	13.6%	19.2%	21.3%	23.4%	30.8%

Interest Expense	(29)	(22)	(20)	(10)	(4)	7	(7)	4
Pre-tax Income	101	279	447	647	1,057	1,221	309	473
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(76)	(60)	(112)	(161)	(242)	(284)	(77)	(119)
Net Income to Company	25	219	335	486	815	937	232	354
% Margin	0.7%	5.6%	7.4%	10.1%	14.7%	16.4%	17.2%	23.3%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	25	219	335	486	815	937	232	354

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	25	219	335	486	815	937	232	354
% Margin	0.7%	5.6%	7.4%	10.1%	14.7%	16.4%	17.2%	23.3%

As Reported
Basic EPS (Continuing Ops)	0.11	1.00	1.52	2.20	3.68	4.18	1.10	1.60
Diluted EPS (Continuing Ops)	0.11	0.99	1.51	2.20	3.68	4.18	1.10	1.60

WA Basic Shares Out.	218.32	219.39	220.50	221.15	221.32	231.66	210.91	221.25
WA Diluted Shares Out.	219.89	220.99	221.37	221.28	221.54	231.88	210.91	221.25

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	101	279	447	647	1,057	1,221	309	473
Addback: Net Interest Expense	29	22	20	10	4	(7)	7	(4)
Addback: Other Non Operating Expenses, Total	19	(9)	3	9	30	30	0	0
Addback: Depreciation & Amortization	137	159	165	167	183	188	66	71
Addback: Restructuring Charges	0	0	1	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	1	0	0	0	0	0	0	0
Addback: Asset Writedown	24	18	1	1	6	6	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0
Adjusted EBITDA	311	469	637	834	1,280	1,438	382	540
% Margin	8.9%	12.0%	14.1%	17.3%	23.1%	25.2%	28.3%	35.5%

Adjusted EBIT	174	310	472	667	1,097	1,250	316	469
% Margin	5.0%	7.9%	10.5%	13.8%	19.8%	21.9%	23.4%	30.8%

Adjusted Net Income Reconciliation
Net Income to Company	25	219	335	486	815	937	232	354
Addback: Unusual Items	25	18	2	1	6	6	0	0
Less: Tax Benefit of Unusual Items (26%)	(7)	(5)	(1)	(0)	(2)	(2)	0	0
Adjusted Net Income	44	232	336	487	819	941	232	354
% Margin	1.2%	5.9%	7.5%	10.1%	14.8%	16.5%	17.2%	23.3%

Loading Error

ALK-Abello B

CPSE:ALKB

Denmark / Healthcare / Pharmaceuticals

5Y Historical Financials